Janney Montgomery Scott LLC Has $426,000 Stock Position in Organon & Co. $OGN

Key Points

• Janney Montgomery Scott LLC significantly reduced its holdings in Organon & Co. by 84.3%, now owning 44,006 shares valued at $426,000.
• Institutional investors collectively own 77.43% of the company's stock, with notable increases in holdings from GAMMA Investing LLC and CWA Asset Management Group LLC.
• Organon & Co. has been rated as a "Moderate Buy" by analysts, with a consensus price target of $17.33 despite a recent quarterly revenue decline of 0.8% year-over-year.

Janney Montgomery Scott LLC lowered its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 84.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,006 shares of the company's stock after selling 235,618 shares during the quarter. Janney Montgomery Scott LLC's holdings in Organon & Co. were worth $426,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its position in Organon & Co. by 186.9% during the first quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock worth $69,000 after purchasing an additional 3,004 shares during the period. CWA Asset Management Group LLC lifted its position in Organon & Co. by 48.9% during the first quarter. CWA Asset Management Group LLC now owns 35,125 shares of the company's stock worth $523,000 after purchasing an additional 11,529 shares during the period. Register Financial Advisors LLC lifted its position in Organon & Co. by 42.2% during the first quarter. Register Financial Advisors LLC now owns 55,426 shares of the company's stock worth $825,000 after purchasing an additional 16,439 shares during the period. Oppenheimer & Co. Inc. lifted its position in Organon & Co. by 67.8% during the first quarter. Oppenheimer & Co. Inc. now owns 54,165 shares of the company's stock worth $807,000 after purchasing an additional 21,887 shares during the period. Finally, HBK Sorce Advisory LLC bought a new stake in Organon & Co. during the first quarter worth about $241,000. Institutional investors and hedge funds own 77.43% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Organon & Co. in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

Organon & Co. Stock Down 1.1%

Shares of NYSE OGN opened at $9.28 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The company has a market cap of $2.41 billion, a price-to-earnings ratio of 3.45, a PEG ratio of 0.84 and a beta of 0.63. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The stock has a 50-day moving average price of $9.93 and a two-hundred day moving average price of $10.02.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business's quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 15th. Organon & Co.'s payout ratio is 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.